EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Successful Clozapine Rechallenge in a 40‐Year‐Old Male Patient With Paranoid Schizophrenia After Clozapine‐Associated Myocarditis

Lukas Zabel, Nathalie Ersek, Andreas B. Hofmann, Lena Machetanz, Johannes Kirchebner, Susanne Stübner

Case Reports in Psychiatry · 2026-01 · 2026 (1)

DOI: 10.1155/crps/3858403 ↗
AbstractBibliografische Angaben

Abstract

Background Clozapine‐associated myocarditis (CAM) is the most common inflammatory adverse effect under clozapine treatment. In the absence of equally effective therapeutic alternatives for treating treatment‐resistant schizophrenia (TRS), clinicians are often faced with the question of whether to rechallenge clozapine in patients who have experienced CAM. However, there is a lack of standardized protocols and published case reports of successful clozapine rechallenge following CAM. Case Presentation A 40‐year‐old patient diagnosed with paranoid schizophrenia experienced CAM during his first clozapine treatment. Four years later, he was successfully rechallenged using a recently published standardized protocol involving a very slow titration schedule. Conclusions Our case adds to the limited number of published cases of successful clozapine rechallenge following CAM. It is the first published case report to use the rechallenge protocol recently published by Qubad et al. (2024), thereby contributing to the development of standardized protocols for the safe and successful clozapine rechallenge following CAM.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →